Challenges to the global control of tuberculosis

Chen Yuan Chiang, Catharina Van Weezenbeek, Toru Mori, Donald A. Enarson

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Diagnosis and treatment of tuberculosis (TB) will likely navigate a historical turning point in the 2010s with a new management paradigm emerging. However, global control of TB remains a formidable challenge for the decades to come. The estimated case detection rate of TB globally was 66%, and there were 310 000 estimated multidrug-resistant TB (MDR-TB) cases among the 6.2 million TB patients notified in 2011. Although new tools are being introduced for the diagnosis of MDR-TB, there are operational and cost issues related to their use that require urgent attention, so that the poor and vulnerable can benefit. World Health Organization (WHO) estimated that globally, 3.7% of new cases and 20% of previously treated cases have MDR-TB. However, the scale-up of programmatic management of drug-resistant TB is slow, with only 60 000 MDR-TB cases notified to WHO in 2011. The overall proportion of treatment success of MDR-TB notified globally in 2009 was 48%, far below the global target of 75% success rate. Although new tools and drugs have the potential to significantly improve both case detection and treatment outcome, adequate health systems and human resources are needed for rapid uptake and proper implementation to have the impact required to eliminate TB. Hence, the global TB community should broaden its scope, seek intersectoral collaboration and advocate for cost reduction of new tools, while ensuring that the basics of TB control are implemented to reduce the TB burden through the current 'prevention through case management' paradigm.

Original languageEnglish
Pages (from-to)596-604
Number of pages9
JournalRespirology
Volume18
Issue number4
DOIs
Publication statusPublished - 2013
Externally publishedYes

Fingerprint

Tuberculosis
Multidrug-Resistant Tuberculosis
Costs and Cost Analysis
Case Management
Health
Therapeutics
Pharmaceutical Preparations

Keywords

  • human immunodeficiency virus
  • multidrug resistance
  • prevention and control
  • treatment outcome
  • tuberculosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Chiang, C. Y., Van Weezenbeek, C., Mori, T., & Enarson, D. A. (2013). Challenges to the global control of tuberculosis. Respirology, 18(4), 596-604. https://doi.org/10.1111/resp.12067

Challenges to the global control of tuberculosis. / Chiang, Chen Yuan; Van Weezenbeek, Catharina; Mori, Toru; Enarson, Donald A.

In: Respirology, Vol. 18, No. 4, 2013, p. 596-604.

Research output: Contribution to journalArticle

Chiang, CY, Van Weezenbeek, C, Mori, T & Enarson, DA 2013, 'Challenges to the global control of tuberculosis', Respirology, vol. 18, no. 4, pp. 596-604. https://doi.org/10.1111/resp.12067
Chiang, Chen Yuan ; Van Weezenbeek, Catharina ; Mori, Toru ; Enarson, Donald A. / Challenges to the global control of tuberculosis. In: Respirology. 2013 ; Vol. 18, No. 4. pp. 596-604.
@article{9a61e87d752f4ba3aa373e7e124a2340,
title = "Challenges to the global control of tuberculosis",
abstract = "Diagnosis and treatment of tuberculosis (TB) will likely navigate a historical turning point in the 2010s with a new management paradigm emerging. However, global control of TB remains a formidable challenge for the decades to come. The estimated case detection rate of TB globally was 66{\%}, and there were 310 000 estimated multidrug-resistant TB (MDR-TB) cases among the 6.2 million TB patients notified in 2011. Although new tools are being introduced for the diagnosis of MDR-TB, there are operational and cost issues related to their use that require urgent attention, so that the poor and vulnerable can benefit. World Health Organization (WHO) estimated that globally, 3.7{\%} of new cases and 20{\%} of previously treated cases have MDR-TB. However, the scale-up of programmatic management of drug-resistant TB is slow, with only 60 000 MDR-TB cases notified to WHO in 2011. The overall proportion of treatment success of MDR-TB notified globally in 2009 was 48{\%}, far below the global target of 75{\%} success rate. Although new tools and drugs have the potential to significantly improve both case detection and treatment outcome, adequate health systems and human resources are needed for rapid uptake and proper implementation to have the impact required to eliminate TB. Hence, the global TB community should broaden its scope, seek intersectoral collaboration and advocate for cost reduction of new tools, while ensuring that the basics of TB control are implemented to reduce the TB burden through the current 'prevention through case management' paradigm.",
keywords = "human immunodeficiency virus, multidrug resistance, prevention and control, treatment outcome, tuberculosis",
author = "Chiang, {Chen Yuan} and {Van Weezenbeek}, Catharina and Toru Mori and Enarson, {Donald A.}",
year = "2013",
doi = "10.1111/resp.12067",
language = "English",
volume = "18",
pages = "596--604",
journal = "Respirology",
issn = "1323-7799",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Challenges to the global control of tuberculosis

AU - Chiang, Chen Yuan

AU - Van Weezenbeek, Catharina

AU - Mori, Toru

AU - Enarson, Donald A.

PY - 2013

Y1 - 2013

N2 - Diagnosis and treatment of tuberculosis (TB) will likely navigate a historical turning point in the 2010s with a new management paradigm emerging. However, global control of TB remains a formidable challenge for the decades to come. The estimated case detection rate of TB globally was 66%, and there were 310 000 estimated multidrug-resistant TB (MDR-TB) cases among the 6.2 million TB patients notified in 2011. Although new tools are being introduced for the diagnosis of MDR-TB, there are operational and cost issues related to their use that require urgent attention, so that the poor and vulnerable can benefit. World Health Organization (WHO) estimated that globally, 3.7% of new cases and 20% of previously treated cases have MDR-TB. However, the scale-up of programmatic management of drug-resistant TB is slow, with only 60 000 MDR-TB cases notified to WHO in 2011. The overall proportion of treatment success of MDR-TB notified globally in 2009 was 48%, far below the global target of 75% success rate. Although new tools and drugs have the potential to significantly improve both case detection and treatment outcome, adequate health systems and human resources are needed for rapid uptake and proper implementation to have the impact required to eliminate TB. Hence, the global TB community should broaden its scope, seek intersectoral collaboration and advocate for cost reduction of new tools, while ensuring that the basics of TB control are implemented to reduce the TB burden through the current 'prevention through case management' paradigm.

AB - Diagnosis and treatment of tuberculosis (TB) will likely navigate a historical turning point in the 2010s with a new management paradigm emerging. However, global control of TB remains a formidable challenge for the decades to come. The estimated case detection rate of TB globally was 66%, and there were 310 000 estimated multidrug-resistant TB (MDR-TB) cases among the 6.2 million TB patients notified in 2011. Although new tools are being introduced for the diagnosis of MDR-TB, there are operational and cost issues related to their use that require urgent attention, so that the poor and vulnerable can benefit. World Health Organization (WHO) estimated that globally, 3.7% of new cases and 20% of previously treated cases have MDR-TB. However, the scale-up of programmatic management of drug-resistant TB is slow, with only 60 000 MDR-TB cases notified to WHO in 2011. The overall proportion of treatment success of MDR-TB notified globally in 2009 was 48%, far below the global target of 75% success rate. Although new tools and drugs have the potential to significantly improve both case detection and treatment outcome, adequate health systems and human resources are needed for rapid uptake and proper implementation to have the impact required to eliminate TB. Hence, the global TB community should broaden its scope, seek intersectoral collaboration and advocate for cost reduction of new tools, while ensuring that the basics of TB control are implemented to reduce the TB burden through the current 'prevention through case management' paradigm.

KW - human immunodeficiency virus

KW - multidrug resistance

KW - prevention and control

KW - treatment outcome

KW - tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=84876927696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876927696&partnerID=8YFLogxK

U2 - 10.1111/resp.12067

DO - 10.1111/resp.12067

M3 - Article

VL - 18

SP - 596

EP - 604

JO - Respirology

JF - Respirology

SN - 1323-7799

IS - 4

ER -